MAKING THE CONNECTION: Between Patients and Providers

An Integrative Approach to the Treatment of Type 1 and Type 2 Diabetes

– Bonus enrichment lecture (*Not accredited) –

Communicating Effectively at the Time of the T2D Diagnosis: What Our Patients Can Teach Us
(Group session facilitated by Steven V. Edelman, MD; and William Polonsky, Phd, CDCES)


With over 50 diabetes medications being approved by the FDA in the past decade and several technologically-advanced diabetes management systems available, there has never been a better time to have diabetes. Led by two endocrinologists who are living with diabetes themselves, and a faculty of experts in the diabetes field, this unique online program will provide real case studies, candid patient testimonials, and cutting-edge strategies to help you help your patients with diabetes reach their treatment goals. Get access to impactful research and practical steps you can implement into your practice to open two-way communication with your patients with diabetes and improve outcomes.

(Please see the full accreditation information here.)

One of the best educational seminars I’ve completed. Loved the presenters who spoke with real working knowledge about the topics.”


*extra-relatable faculty (they're living with type 1)



Founder & Director, TCOYD; Endocrinologist, Clinical Professor of Medicine, University of California, San Diego (UCSD) School of Medicine; Director, Diabetes Care Clinic, VA Medical Center San Diego

Dr. Edelman is a professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California, San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego. Dr. Edelman, who has type 1 diabetes himself, has written more than 200 articles, five books, and has won numerous awards for teaching and humanitarianism. He has been chosen by the medical students at UCSD as the ‘teacher of the year’ numerous times. Among his many honors, Dr. Edelman has received the ‘Diabetes Educator Of The Year’ award by the American Diabetes Association, the ‘Distinction in Endocrinology’ award by the American Association of Clinical Endocrinologists, and named ‘Top 1% of U.S. Endocrinologists’ by US News and World Report.

Effective Use of Oral Medications for Type 2 Diabetes: Lowering Cardio-renal Risk While Improving Glycemic Control



Type 1 Track & Professional Education Director, Endocrinologist, Associate Professor of Medicine, UCSD School of Medicine

Dr. Jeremy Pettus was diagnosed with type 1 diabetes when he was 15 years old. Since that time he has dedicated his career to educating and treating others like himself. He is currently an Endocrinologist and Associate Professor of Medicine at the University of California, San Diego. There, he focuses primarily on clinical trials to develop and test new and innovative therapies for people living with diabetes. These include studies ranging from medications to reverse or slow the disease once it occurs, to islet cell transplantation strategies, to device studies such as artificial pancreas technology. As somebody who has the disease himself, sees patients with type 1, and is actively working on curing/treating the disease, we are honored to have him at TCOYD.

Focus on Time in Range and Modern Management of Type 1 Diabetes



CEO, Principal Investigator, National Research Institute

Dr. Frias, a native of Chile, is currently President and Principal Investigator of National Research Institute in Los Angeles, CA. He completed his undergraduate studies at the University of Florida and received his medical degree from Vanderbilt University School of Medicine. Dr. Frias has held leadership positions in Clinical and Medical Affairs at Eli Lilly, Amylin Pharmaceuticals, Pfizer, and Johnson and Johnson, where he served as Chief Medical Officer and Global Vice President of Clinical and Medical Affairs, Diabetes Care. He has held academic positions at the University of Colorado Health Sciences Center, Barbara Davis Center for Diabetes, and the University of California San Diego School of Medicine, where he is currently on the clinical faculty.

Injectable Agents and Cardiovascular Effects



Clinical Psychologist; Founder & CEO, Behavioral Diabetes Institute

Dr. Polonsky is President and Founder of the Behavioral Diabetes Institute, the world’s first organization totally dedicated to studying and addressing the unmet psychological needs of people with diabetes. He is also Associate Clinical Professor in Psychiatry at the University of California, San Diego. Dr. Polonsky received his PhD in clinical psychology from Yale University and has served as Senior Psychologist at the Joslin Diabetes Center in Boston, faculty member at Harvard Medical School and Chairman of the National Certification Board for Diabetes Educators. A licensed clinical psychologist and certified diabetes educator, he received the American Diabetes Association’s 2014 Richard R. Rubin Award for distinguished contributions to behavioral medicine and psychology.

Diabetes Distress: What It Is, Why It Is Important, and What To Do About It

Overall fantastic program. Has helped give me more clarity and confidence in treating DM than any other CME so far on this topic.”


We focus on four distinct areas of the most cutting-edge diabetes management strategies:
•  Patient-provider relationships with a focus on communication methods to improve adherence and persistence 
•  Oral agents for the treatment of type 2 diabetes and their effect on cardiovascular and renal health 
•  Injectable therapies, including insulin, for use in patients with type 2 diabetes and their cardiovascular and obesity impact
•  Time in range, adjunctive therapies, hybrid closed loop systems and the unmet needs of type 1 diabetes


Upon completion of these activities, participants should be able to:
1. Identify the different pathophysiologic defects associated with type 2 diabetes and how all the pharmacologic agents (oral and injectable) address these specific abnormalities including patients with very poor glycemic control and elevated insulin requirements.
2. Discuss the recently published cardiovascular-renal outcome trials on oral (SGLT2 inhibitors) and injectable type 2 medications (GLP1-RAS). 
3. Evaluate the use of SGLT-2 and GLP-1 RA in patients who have cardiovascular risks factors and are at risk or have a history of atherosclerotic cardiovascular disease (ASCVD).
4. Design a treatment plan for multiple daily injection regimens and insulin pump therapy including hybrid closed loop systems. 
5. Select effective therapeutic adjustments based on CGM trending or rate of change arrows, time in range, and standard deviation. 
6. Recognize the physical and emotional barriers that prevent patients with diabetes from being persistent and adherent to their therapeutic regimen(s). 
7. Discuss innovative and dynamic strategies for communication with patients to strengthen provider-patient relations.


This course is designed for diabetes healthcare providers including endocrinologists, primary care physicians, nurse practitioners, physician assistants, nurses, certified diabetes educators, pharmacists, registered dietitians, and other healthcare providers wanting to expand their knowledge of diabetes management.

This activity is jointly provided by Global Education Group and Taking Control Of Your Diabetes.

This activity is supported by an educational grant from Medtronic, Abbott Diabetes Care, Dexcom, Novo Nordisk, and Vertex.


(ACCME reciprocity is not guaranteed but may be offered depending on your board. Please consult your board to request ACCME reciprocity for this course.

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Taking Control of Your Diabetes.  Global is accredited by the ACCME to provide continuing medical education for physicians.


Physician Credit Designation

Global Education Group designates this enduring material for a maximum of 4.0 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 4.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.


Credit Designation

Global Education Group designates this continuing education activity for 4.0 contact hour(s) (0.40 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – 0530-9999-22-090-H01-P)

This is a knowledge-based activity.

Dietitian Accreditation Statement

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

*CDR learners may submit their program evaluation directly to the CDR


Nurse Practitioner Continuing Education

This activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and (name of other entity). Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 4.0 contact hour(s) (which includes 0.1 hour(s) of pharmacology).


Certified Diabetes Educator Accreditation Statement

This program is joint provided with the Association of Diabetes Care & Education Specialists, an approved provider on the CBDCE list of Approved Providers.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global.  All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.


All relevant financial relationships have been mitigated.


The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter Reported Financial Relationship
Steven V. Edelman, MD Advisor: AstraZeneca, BrightSight, InPen, Lexicon, Lilly USA, LLC, MannKind Corporation, Merck, Sanofi-aventis U.S. Inc.

Consultant: Sensionics, Team Type 1

Speakers’ Bureau: AstraZeneca, Lilly USA, LLC, MannKind Corporation, Merck, Sanofi-aventis U.S. Inc.

Juan Pablo Frias, MD Constulant: Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, Sanofi

Research: Akero, AstraZeneca, Boehringer Ingelheim, BMS, 89bio, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel, Sanofi

Honoraria: Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, 89bio, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer, Sanofi

Speakers’ Bureau: Eli Lilly, Merck, Sanofi

Jeremy Pettus, MD Consultant: Carmot, Diasome, Novo Nordisk, Sanofi

Speakers’ Bureau: MannKind, Sanofi

William H. Polonsky, PhD, CDCES Consultant: Abbott Diabetes Care, Boehringer Ingelheim, Dexcom, Eli Lilly, Insulet, Intuity, MannKind, Novo Nordisk, Provention bio, Sanofi

Stock Shareholder: Provention Bio, Teladoc


The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RN Nothing to disclose
Kristin Delisi, NP Nothing to disclose
Amanda Turner MS, RDN, CSSD Nothing to disclose
Lindsay Borvansky Nothing to disclose
Andrea Funk Nothing to disclose
Liddy Knight Nothing to disclose
Ashley Cann Nothing to disclose
Sarah Severance Nothing to disclose

Term Offering

This activity was released on 5/23/2022 and is valid for one year. Requests for credit must be made no later than 5/23/2023.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Instructions to Receive Credit

In order to receive credit for this activity, the participant must register for the event, complete the accredited modules (4), and successfully complete the post test and evaluation.


  1. Go to this web address:
  3. Click on the link representing your profession
  4. Fill out the complete credit application form and click “Continue to Post-test”
  5. Complete the post-test and click “Continue”
  6. Complete the evaluation form and click “Submit”
  7.  Successful applicants will be able to download a certificate, and a copy of the certificate will also be emailed to you. (Pharmacists will receive instructions on the certificate.)

System Requirement

1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
512 MB of RAM (1 GB recommended)Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google ChromeFor HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
1.83 GHz Intel Core Duo or faster processor
512 MB of RAM (1 GB recommended)
MAC OS X 10.12, 10.13 and 10.14Mozilla Firefox, Apple Safari, Google ChromeFor HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)

Fee Information & Refund/Cancellation Policy

This is a complementary activity.


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Taking Control of Your Diabetes do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.